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Background: One of the unique characteristics of the female genital tract is the extensive tissue remodeling
observed throughout the menstrual cycle. Multiple components of the extracellular matrix take part in this tissue
rebuilding; however, the individual components involved have not been identified.
Methods: In the present study, the expression of extracellular matrix proteins and selected matrix
metalloproteinase (MMP) activities in Fallopian tubes (FT) throughout the menstrual cycle were examined by PCR
array, immunocytochemistry, zymography and bioinformatics.
Results: Of the eighty-four genes analyzed, eighty-three were expressed in the FT during at least one stage of the
menstrual cycle. We observed a significant increase (>/=2-fold) in ADAMTS1, ADAMTS13, COL7A1, MMP3, MMP9,
PECAM1, and THBS3 in the periovulatory phase compared to the follicular phase. Meanwhile, we observed a
significant decrease (>/= 2-fold) in COL7A1, ICAM1, ITGA8, MMP16, MMP9, CLEC3B, SELE and TIMP2 in the lutheal
phase compared to the periovulatory phase. Immunocytochemistry showed that MMP-3 and MMP-9 were localized
in the endosalpinx during all phases of the menstrual cycle. Gelatin zymograms detected non-cycle-dependent
protease activity.
Conclusions: Several extracellular matrix components were regulated throughout the menstrual cycle in a cyclic
pattern, suggesting a possible steroid regulation and a role in tissue remodeling and FT functions.
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One of the unique characteristics of the female genital
tract is its extracellular matrix (ECM) layer, which plays a
key role in the regulation of reproductive function. The
ECM determines cell migration, division and differenti-
ation, and ultimately cell survival or death. The ECM is
regulated by a complex network of paracrine mediators
[1], including matrix metalloproteinases (MMPs) and their
endogenous inhibitors, the tissue inhibitors of metallopro-
teinases (TIMPs). MMPs participate in the degradation of
the ECM [2], and more than 30 MMPs have been* Correspondence: luis.velasquez@unab.cl
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reproduction in any medium, provided the ordescribed in vertebrates, of which 27 are present in
humans [3]. The ECM was long considered to be a passive
structure that provided anchoring and mechanical support
to the cells, and the extracellular proteases were thought
to be simple remodelers of the ECM [4]. However, it is
now generally accepted that the ECM is an active struc-
ture that contains growth factors, binding proteins and
other bio-molecules, as well as binding sites for cellular
surface molecules that are exposed only after undergoing
proteolysis. Thus, the proteases responsible for the re-
newal of the ECM contribute dynamically to cellular inter-
actions [5,6] and also have complementary effects on the
recruitment of lymphocytes [7] and the processing of
cytokines into their active forms [8].
Because of their potential to modify tissue, MMPs are
strictly regulated at multiple levels, including transcription. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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localization (within or outside the cell) and internalization
by endocytosis. MMPs are secreted as inactive zymogens,
and once activated, several mechanisms can regulate
MMP activity [9-11]. Four types of MMP inhibitors are
present in the extracellular spaces and in body fluids. The
most relevant of these inhibitors are the TIMPs, which
are 20–30 kDa proteins that interact directly with the
active site(s) of MMPs. At present, four TIMPs have
been described, namely, TIMP-1, TIMP-2, TIMP-3 and
TIMP-4, although all of the TIMPs can inhibit all MMPs,
TIMP-1 preferentially inhibits MMP-9, and TIMP-2 pre-
ferentially inhibits MMP-2 [3,12]. TIMPs are widely
expressed in all tissues, and they are regulated jointly with
the MMPs in most cases. In addition to inhibiting MMPs,
the TIMPs participate in cell differentiation functions; e.g.,
TIMP-1 stimulates proliferative activity in endothelial cells
[13], TIMP-2 stimulates fibroblast growth [14], and
TIMP-3 induces apoptosis in the cells of the vascular
smooth muscle [15].
Metalloproteinases are involved in regulating many of
the structural ECM changes that occur during repro-
ductive processes, participating actively in ovulation,
menstruation, decidualization, trophoblast implantation,
fetal development, and cervical dilation during childbirth
[10,16-19]. In addition, embryonic developmental events,
are characterized by cell migration processes, changes in
tissue morphology, and the extensive restructuring of
the ECM, which correlate with high levels of MMPs [20-
25]. Notably, the activity of ovarian and uterine MMPs is
regulated by the sex steroids, growth factors and cyto-
kines that regulate reproductive function. However, des-
pite the fact that the FT are subject to the same type of
paracrine regulation, the MMP system has not been
described in this organ, and its regulation during the
menstrual cycle is also not known, thus limiting our
understanding of tubal physiology and pathology and




All protocols were approved by the ethics and biosafety
committee of the Servicio de Salud Metropolitano Norte
and were in accordance with the ethical standards
recommended by the Helsinki Declaration (1975). The
FTs were obtained only from women undergoing surgi-
cal sterilization for reasons unrelated to this study and
written informed consent was obtained from each par-
ticipant of this study. The tissues were collected in col-
laboration with the Servicio de Ginecología y Obstetricia
of the Hospital San José. The patients were fertile, 25 to
45 years of age, and voluntarily requested surgical
sterilization. The patients fulfilled all of the requirementsfor the surgical procedure, as well as all of the criteria
for inclusion in the study. Exclusion criteria included
having suffered a sexually transmitted infection, tubal
disease, PID, endometriosis, having used hormonal
contraceptive methods within three months before sur-
gery and heavy use of alcohol, tobacco or drugs abuse. A
blood sample was obtained during each procedure such
that the cycle stage could be assessed using plasma levels
of estradiol and progesterone together with menstrual
history. The piece of FT removed by laparoscopy was al-
ways the ampular segments.Processing of Fallopian tubes sampled at different stages
of the menstrual cycle
The FT were processed in the laboratory immediately
following extirpation using our standard method [22]
and subsequently maintained in Dulbecco's Modified
Eagle Medium (DMEM) at 37°C, 5% (v/v) CO2. The FT
explants (1 cm2) were maintained for 24 h in culture
medium to stabilize them and to ensure the absence of
contaminating microorganism(s).RNA preparation
Total RNA was extracted from samples with TRIZOL
(Invitrogen, USA) according to the manufacturer’s proto-
col. Contaminating genomic DNA was removed by
RNase-free DNase (QIAGEN, USA). RNA yield, purity
and concentration were determined by spectrophotom-
etry, and 1 μg of each RNA was run on a 1% agarose gel
(Invitrogen, USA) to ensure RNA integrity. The RT2 first-
strand kit (Qiagen, USA) was used to convert 1 μg of
RNA to cDNA according to the manufacturer’s protocol.ECM and adhesion molecule quantitative PCR arrays
Screening for the expression of 84 cell adhesion-related
genes and ECM molecules in FT in 12 samples (four in
the follicular phase, four in the periovulatory phase and
four in the luteal phase; n = 12, duplicate arrays per FT
sample) was conducted using the Human ECM and Ad-
hesion Molecules RT2 Profiler PCR array (SaBiosciences
Corp., Frederick, MD, USA) according to the manufac-
turer’s instructions. In brief, cDNA was prepared from
1 μg total RNA using the RT2 first-strand kit. PCR amp-
lification was conducted with an initial 10-min step at
95°C followed by 40 cycles of 95°C for 15 s and 60°C for
1 min. The fluorescent SYBR Green signal was detected
immediately after the extension step of each cycle, and
the cycle when the fluoresence reach 0.1, was recorded
as the cycle threshold. Data were imported into an Excel
database and analyzed using the comparative cycle
threshold method. The raw data were normalized to
B2M, HPRT1 and RPL13A.
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Immunocytochemistry in nine FT samples was performed
using anti-human antibody MMP9 (1:100 dilution, A b D
Serotec, USA) and anti-human MMP3 (1:250 dilution, A
b D Serotec, USA), respectively. Human placenta has been
used as a positive control for the detection of both anti-
gens. For the negative control, the first antibody was omit-
ted from the reaction. Briefly, tissue sections were cut in
5 mm pieces and fixed with 4% Paraformaldehyde for
2 hours. Pieces were deep in a saccharose gradient (5% -
20%), embedded in OCT and stored at −20°C. Fixed sam-
ples on slides were rehydrated and treated with 1,5%
hydrogen peroxide in distilled water for 30 min to block
endogenous peroxidase activity. Cells were then washed
with Phosphate-buffered saline-Tween 0,1% (PBS-Tween)
and incubated with non-immune block for 60 min. Pri-
mary antibody was applied and incubated at 4°C for 16 h,
followed by HistostainW-SP kits (Invitrogen, USA) accord-
ing to the manufacturer’s instructions. Tissue sections
were counterstained with Harris hematoxylin (Sigma,
USA), air-dried and mounted. Finally, the background was
subtracted using the software Image J (NIH,USA).
Detection of MMP-associated gelatinolytic activity by
zymography
Briefly, 25 μg of protein (determined by Bradford) from
nine FT explant was subjected to electrophoresis on acryl-
amide/bisacrylamide gels copolymerized with gelatin. The
presence of the different MMPs was determined based on
the corresponding molecular weights of the visualized
proteolytic bands and compared with pre-stained molecu-
lar weight marker standards and the corresponding posi-
tive MMP controls (Sigma, USA). The presence of SDS
within the gels also allows the latent forms of proMMP-2
and proMMP-9 to be visualized. Enzyme activities in the
gel were quantified with respect to both the surface and
the intensity of the bands using an image analysis program
(Biosciences gel systems, USA) and expressed in arbitrary
densitometric units relative to the control (value of 1)
MMP standard (Sigma, USA).
Bioinformatics
The set of genes identified was analyzed using Gene
Network Pro (Bioscience, USA), to identify cellular inter-
actions previously described in other cell types.
Statistical analyses
Data are expressed as the mean± SD cycle threshold
(Ct) for each sample and gene, and these data was used
to calculated fold change in each phase. Student’s t-test
was used when comparing two phases; follicular v/s
periovulatory and periovulatory v/s lutheal, p-value
<0.05 was considered significant.Results
ECM and adhesion molecules quantitative PCR arrays
Of the 84 genes analyzed, 83 were expressed during
some phase of the menstrual cycle, See additional file 1:
Table S1.
Figure 1A shows the gene expression profile in the fol-
licular phase versus the periovulatory phase when estra-
diol is the dominant hormone, and Figure 1B shows the
periovulatory phase versus the luteal phase when proges-
terone is the dominant hormone. The expression profile
of the genes studied shows that these genes tend to in-
crease their expression in the periovulatory phase and
decrease their expression in the luteal phase. These cyc-
lical fluctuations in gene expression suggest that the ex-
pression of these genes is regulated by estradiol and
progesterone.
When comparing the gene expression levels in the fol-
licular phase versus the periovulatory phase, we found
statistically significant differences in the expression of 7
genes (i.e., a ≥2-fold change). The p value and the fold
change of each gene are detailed in Table 1.
When comparing the gene expression levels in the
periovulatory phase versus the luteal phase, we found
statistically significant differences in the expression of 8
genes. The p value and the fold change of each gene are
detailed in Table 2.
Of the 8 genes with significant differences in gene ex-
pression levels during certain phase of the menstrual
cycle, only COL7A1 and MMP9 showed significant dif-
ferences in both phases of the menstrual cycle.
Immunocytochemistry
Immunocytochemistry was used to localize the MMP3
and MMP9 proteins in histological FT sections in the
follicular, periovulatory and luteal phases. All samples
display a strong reaction in the endosalpinx, where the
signal would be expected according to the functions per-
formed by metalloproteinases in other tissues. The nega-
tive controls in which the primary antibody was omitted
did not show any staining, indicating that the signal was
specific (Figure 2).
Detection of MMP-associated gelatinolytic activity by
zymography
Zymographic analyses were performed with selected
samples of all phases of the menstrual cycle. As shown
in Figure 3, all samples exhibited gelatinase activity.
Densitometric analysis of Western blots showed that
MMP2 and MMP9 were expressed at similar levels in all
phases of the menstrual cycle (data not shown).
Bioinformatics
The set of genes identified was analyzed using Gene































































































Figure 1 Three-dimensional graph representing the gene expression levels in the PCR array plate. The axes x and y are the coordinates
that identify the genes and the Z axis represents the individual gene expression levels after comparing the follicular phase versus periovulatory
phase (panel 1A) and the periovulatory phase versus the luteal phase (panel 1B). In both cases B2M, HPRT1 and RPL13A were use as normalizing
agents. The color lines represent the estradiol and progesterone levels throughout the menstrual cycle.
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eral potential interactions between the identified genes,
including physical interactions between MMP3/MMP9
[26] and between MMP3/TIMP-2 [27]; this analysis also
suggested that MMP3 would be able to induce the acti-
vation of the MMP9 precursor. In turn, active MMP9
can inhibit TIMP-2 [27]. Finally, Selectin E and Cam1
participate in the NFkB pathway [28]. The potential
interactions identified are detailed in Figure 4A. We also
analyzed the potential regulatory pathways on TIMP-2,
considering the variety and complexity of the interactionsTable 1 Genes with significant changes in gene
expression between the follicular and periovulatory
phases
Symbol P-value Fold regulations Molecular Class
ADAMTS1 0.018 2.47 Metalloproteinases
ADAMTS13 0.044 3.52 Metalloproteinases
COL7A1 0.003 3.21 Structural collagen fibers
MMP3 0.014 4.01 Metalloproteinases
MMP9 0.036 3.60 Metalloproteinases
PECAM1 0.031 2.88 Cell adhesion protein
THBS3 0.009 2.28 Cell adhesion proteinin which seems to be a crucial point in the cell regulation
[27,29-32].
Discussion
The main objective of this study was to determine how
genes related to the extracellular matrix are expressed in
the FT throughout the menstrual cycle. We used a PCR
array plate that contained 84 genes selected for their role
in extracellular matrix remodeling in various cell types.
An analysis of the overall behavior of this set of genes
shows that 83 of the 84 genes are expressed in the FT
during at least one phase of the menstrual cycle. These
genes tend to be expressed at greater levels in theTable 2 Genes with significant changes in expression
between the periovulatory and luteal phases
Symbol P-value Fold regulations Molecular Class
COL7A1 0.009 −4.24 Structural collagen fibers
ICAM1 0.049 −2.60 Glycoprotein
ITGA8 0.038 −2.91 Integrin, cell junction
MMP16 0.026 −14.32 Metalloproteinases
MMP9 0.008 −3.24 Metalloproteinases
CLEC3B 0.040 −11.19 Secreted polypeptide
Figure 2 Immunostainig of MMP-9 and MMP-3 in sections of human FT ampulla, throughout the menstrual cycle. Positive staining of
MMP-9 in follicular phase at lower magnification (A); note the complete absence of label in negative control in the small square at the right (B).
Staining of MMP-9 at higher magnification in follicular (C), periovulatory phase (D) and luteal phase (E). Positive staining of MMP-9 in follicular
phase (F), periovulatory phase (G) and luteal phase (H). Note the similar stromal distribution of MMP-9 and MMP-3 in the sections. The arrows
indicates positive brown immunostaining, counterstaining was performed with hematoxylin. Scale bar = 100 μm.
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show reduced expression during the luteal phase. These
results probably indicate that this set of genes is regu-
lated by estradiol and progesterone.
Statistical analysis showed that 7 genes undergo a two-
fold increase in expression in the periovulatory phase
compared to follicular phase. Of these genes, 1 encodes
a structural protein (COL7A1), 4 encode genes that
modify the extracellular matrix through proteolysis
(ADAMTS1, ADAMTS13, MMP3, and MMP9) and two
are involved in cell adhesion (PECAM1 and THBS3).
Briefly, ADAMTS1 (disintegrin and metalloproteinase
with thrombospondin motif 1) has been associated with
inflammatory processes, and its activity could be related
to salpingitis triggered by sexually transmitted pathogens
[33,34]. In addition, this gene is necessary for the devel-
opment and functionality of the genital tract in rodents
[35]. ADAMTS13 (ADAM metallopeptidase with throm-
bospondin type 1 motif 13) functions as a disintegrin
and metalloproteinase with a thrombospondin motif.
The enzyme encoded by this gene is the protease that
cleaves the von Willebrand factor (vWF). Thus, this pro-
tein may participate in leukocyte migration that occursFigure 3 Matrix metalloproteinase MMP-2 and MMP9 detected on FT
standard (Std) obtained from a commercial company. (A) Representative g
active MMP2 and MMP9 throughout the menstrual cycle. Data shows ninein the fallopian tubes under both normal and patho-
logical conditions. COL7A1 encodes the alpha chain of
collagen type VII. The collagen fiber is expressed exclu-
sively below the basal epithelial cells, and mutations in
COL7A1 are associated with structural changes [36].
MMP3 is involved in the degradation of the extracellular
matrix in several tissues [37] and is important for em-
bryonic development, reproduction and tissue restruc-
turing. MMP3 has also been associated with pathological
processes [38], such as tumor metastasis and arthritis.
PECAM1 (platelet/endothelial cell adhesion molecule 1)
is expressed on the surfaces of platelets, neutrophils and
T cells and at intercellular junctions in various cell types.
This protein is a member of immunoglobulin superfam-
ily and is involved in leukocyte migration, angiogenesis,
and integrin activation [39]. THBS3 (thrombospondin 3)
is an adhesive glycoprotein that is involved in cell-cell
and cell-matrix interactions.
Eight genes exhibited a twofold or greater decrease in
their expression in the luteal phase compared to the
periovulatory phase. These genes encode proteins with
structural functions, including proteolytic functions in
the extracellular matrix (MMP16, MMP9, and TIMP2),on follicular, periovulatory and luteal phases. MMP-2 and MMP-9
elatin zymogram of three separate experiments illustrating pro and



















Figure 4 Bioinformatic analysis. Bioinformatic analysis of the genes identified to determine the potential cellular interactions between them
(A). We also analyzed the potential regulatory pathways on TIMP-2, considering the variety and complexity of the interactions in which seems to
be a crucial point in the cell regulation (B).
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(ICAM1, ITGA8, and SELE). COL7A1 is a structural
protein, and CLEC3B participates in signal transduction
process. Briefly, MMP16 activates MMP2 by cleavage in
other cell systems. MMP9 (gelatinase B, 92 kDa gelati-
nase, 92 kDa type IV collagenase) degrades collagen IV
and V. Murine studies suggest that it has a role in tissue
remodeling associated with tumor development. TIMP2
is an inhibitor of matrix metalloproteinases and the only
TIMP family member capable of suppressing the prolif-
eration of endothelial cells. This protein is critical for
maintaining tissue homeostasis by limiting tissue prolif-
eration in response to angiogenic factors and inhibiting
protease activity in tissues subjected to matrix remodel-
ing. ICAM1 (intercellular adhesion molecule 1) is a cell
surface glycoprotein that is typically expressed in endo-
thelial cells and immune cells. This protein binds to
CD11a/CD18- or CD11b/CD18-type integrins. SELE (E-
selectin) is expressed on cytokine-stimulated endothelial
cells and is believed to be responsible for the accumula-
tion of leukocytes at sites of inflammation. Selectins are
cell adhesion molecules that could be involved in the
interaction between leukocytes and endothelium, as
well as in the pathogenesis of atherosclerosis. CLEC3B
(C-type lectin domain family 3, member B) is also
downregulated in the luteal phase [40].
Using immunocytochemistry, we determined that
MMP2 and MMP9 are expressed in the endosalpinx in a
location consistent with a role in the remodeling of the
fallopian tubes. Because MMPs are one of the principal
regulators of the extracellular matrix, zymograms wereperformed at different stages of the menstrual cycle.
These zymograms showed that MMP2 and MMP7 are
expressed in the fallopian tube and that their enzymatic
activity increases during the periovulatory phase, which
is consistent with gene expression determined by PCR
screen.
According to data from our bioinformatics analysis
(Figure 4A), MMP9 and MMP3 negatively regulate
TIMP2, suggesting that increasing the relative amount
of MMP9 and MMP3 should decrease the relative
amount of TIMP2, but this does not occur. Therefore,
we analyzed the cellular interactions involved in the
regulation of TIMP2 (Figure 4B) and analyzed the rela-
tive amounts of each gene. MMP14 and MMP2 showed
the highest relative expression during different phases
of the menstrual cycle in the initial PCR screen. In
other cell systems, MMP14 increases the expression of
TIMP2, which could explain the increase in TIMP2
during the periovulatory phase and its subsequent de-
crease in the luteal phase.
Like all reproductive tissue, the extracellular matrix of
the FT should be remodeled during the luteal phase.
Therefore, we analyzed the expression of genes related
to matrix remodeling in other cell models. Several
metalloproteinases were found to maintain their expres-
sion through the menstrual cycle, as shown in Figure 3.
However, there was a decrease in the expression of
MMP inhibitors (TIMPs) during the luteal phase, which
could be related to extracellular matrix remodeling in
human fallopian tubes during the luteal phase. This
piece of information will be important for the generation
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logical tubal morphology.
Conclusions
The overall results suggest that proteins related to extra-
cellular matrix remodeling could participate in the
changes that occur in the fallopian tube throughout the
menstrual cycle, and these proteins are probably regu-
lated directly or indirectly by estradiol and progesterone
of ovarian origin. The specific role of each of the mole-
cules identified must be defined in future studies. The
function of the genes identified fits perfectly in the nor-
mal and pathological physiology of the TF, however the
specific role of each of the molecules identified must be
defined in future studies.
Additional file
Additional file 1: Table S1. Gene expression levels of 84 genes related
with extracellular matrix and adhesion proteins. The expresión levels in
the diferentes phases of the menstrual cycle were expressed using 2-ΔCT
formula (Columns B to D). The fold of changes in each phase is indicated
in the columns E, F, G and was calculated with the 2-ΔΔCT algorism.
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